Glucotrack repurchased over 90% of its Series A Warrants, strengthening its capital structure and demonstrating confidence in product development.

Following the repurchase, approximately 4,300 Series A Warrants remain outstanding of which majority of these are also expected to be repurchased.

Following the repurchase, approximately 4,300 Series A Warrants remain outstanding of which majority of these are also expected to be repurchased. The Series B Warrants were previously extinguished in ...